查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
NPS+(美國)- 前列腺癌症
市場調查報告書
商品編碼
1803887

NPS+(美國)- 前列腺癌症

NPS+ (US) - Prostate Cancer
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告探討了美國腫瘤學家對前列腺癌治療的看法，並對領先療法的品牌忠誠度、滿意度和市場佔有率進行了深入分析。報告探討了影響醫生處方決策的因素、領先品牌的比較表現以及最能引起臨床醫生共鳴的訊息。

透過淨推薦值 (NPS+) 指標和定性回饋，本報告提供了關於品牌健康狀況、滿意度驅動因素以及易受品牌轉換影響的領域的可行洞察，從而支持醫藥專業人士的策略決策。

主要的問題

  • 1.比較不同品牌的 NPS 得分
  • 2.醫師對特定品牌的忠誠度如何？
  • 3.哪些品牌訊息能引起醫師的共鳴？
  • 4.影響醫師選擇的關鍵因素有哪些？
  • 5.主要品牌的市佔率是多少？
  • 6.各主要品牌與其競爭對手相比如何？
  • 7.由於品牌滿意度低，哪些品牌最有可能被消費者取代？

領導品牌

  • Aquiga
  • Lynparza
  • Nubeqa
  • Orgovix
  • Pluvicto
  • Rubraca
  • Talzenna
  • Xofigo
  • Xtandi

調查手法:

FirstView 報告是基於透過 LiMATM 選定的醫生進行的定量調查而得出。 LiMATM 是全球最大的醫生名錄，擁有超過 300 萬名醫生。每位醫生均根據嚴格的篩選標準精心挑選，以確保收集到的見解具有相關性和可靠性，反映頂尖醫療專業人士的真實意見和經驗。調查結果以易於理解的圖表形式呈現，方便您快速理解和分析數據。憑藉 LiMATM 的廣泛覆蓋範圍和準確性，FirstView 報告可提供無與倫比的數據驅動洞察，指導策略規劃，並幫助您在快速發展的醫療保健領域保持領先地位。

我們的報告有何獨特之處？

FirstWord Reports 是值得信賴的行業領導者，專注於製藥領域，為生物製藥專業人士和決策者提供深入可行的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察，幫助客戶了解新興趨勢並有效應對複雜挑戰。憑藉廣泛的研究以及來自領先專家和關鍵意見領袖 (KOL) 的獨立、公正的見解，我們的報告能夠提供您所需的準確性和可靠性。獨家訪談和數據，以及持續的市場監測，確保您能夠全面了解市場動態。我們的報告涵蓋 40 多個活躍的疾病領域，並提供醫生情報，包括關鍵意見領袖洞察和定量醫生調查，以及行業專家對醫療事務、數位健康、銷售和營銷、市場准入等領域問題的看法，使您能夠做出更明智的數據驅動決策，並在快速變化的行業中保持競爭力。

簡介目錄

This report examines US oncologists' perspectives on prostate cancer therapies, providing a detailed analysis of brand loyalty, satisfaction, and market share among leading treatments. It explores the factors influencing physician prescribing decisions, the comparative performance of major brands, and the messages that resonate most with clinicians.

Through Net Promoter Score (NPS+) metrics and qualitative feedback, the report offers actionable insights into brand health, drivers of satisfaction, and areas where brands may be vulnerable to switching, supporting pharmaceutical professionals in strategic decision-making.

Key Questions Answered:

  • 1. How do NPS scores by brand compare?
  • 2. How loyal are physicians to specific brands?
  • 3. What brand messages resonate with physicians?
  • 4. What are the key factors driving physician choice?
  • 5. What is the market share of leading brands?
  • 6. How does each of the leading brands compare to its competitors?
  • 7. Which brands are vulnerable to switching due to low brand satisfaction?

Key Brands:

  • Akeega (abiraterone acetate/niraparib)
  • Lynparza (olaparib)
  • Nubeqa (darolutamide)
  • Orgovyx (relugolix)
  • Pluvicto
    (lutetium-177 vipivotide tetraxetan)
  • Rubraca (rucaparib)
  • Talzenna (talazoparib)
  • Xofigo (radium-223 chloride
  • Xtandi (enzalutamide)

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.